Aarti Pharmalabs Ltd

- The transcript does not mention any current or planned fundraising through debt or equity. - No specific details or discussions about raising funds via equity or debt instruments were provided during the Q1 FY25 earnings call. - The focus was primarily on capacity expansions (Xanthine project, Atali project) and operational updates funded through internal accruals or ongoing CAPEX plans. - Total CAPEX guidance for FY25 is around Rs. 500-550 crores, including Rs. 150 crores for Xanthine and Rs. 375 crores for the Atali project, with no mention of external fundraising. - Management has not indicated any intentions to raise additional capital through the markets as of this call.

- **Xanthine Expansion:** Approx. Rs. 150 crore CAPEX planned for expanding Xanthine production capacity from 5000 to 9000 metric tonnes across two sites, expected completion by early FY26. - **Atali Project:** Rs. 375 crore outlay for Atali facility focused on CDMO/CMO and Intermediate manufacturing, expected to commission by Q4 FY25; will add 400–500 KL capacity, increasing overall capacity by 25-30%. - **Vapi Site Expansion:** Semi-commercial block for small to medium batch sizes commissioning expected in Q2 FY25 to support early phase CDMO/CMO projects. - **Solar Power Plant:** Rs. 90 crore investment in a new solar power plant at Akola, Maharashtra, expected to commission in the current quarter and cover one-third of power requirements, reducing manufacturing costs. - **Total FY25 CAPEX:** Estimated Rs. 500-550 crore encompassing the above projects. These investments aim to drive capacity expansion, support CDMO business growth, and improve cost efficiencies.

- CDMO/CMO business expects strong growth of 25% to 30% year-on-year in FY25 driven by increased inquiries and projects due to US Biosecure Act and China Plus One strategies. - Expansion projects like Atali facility commissioning by Q4 FY25 will add 400-500 KL capacity, increasing capacity by about 25-30%, supporting future demand surge. - Xanthine segment capacity is being expanded to 9000 MT by early FY26, addressing demand growth. - Semi-commercial block at Vapi site operational in Q2 FY25 will enable small to medium batch size productions. - Despite competition in Xanthine prices, export share grew to 57% this quarter, indicating volume growth potential. - The Company aims for consolidated EBITDA growth of 10%-12% in FY25 and a long-term annual growth target of approximately 15%. - Multi-stage CDMO projects' growth expected as more projects move from early to commercial stages.

- Company maintains guidance of approximately 10% to 12% EBITDA growth in FY25. - Long-term goal is around 15% annual growth in earnings over the next three years. - CDMO/CMO segment expected to grow strongly by 25% to 30% year-on-year in FY25, driven by new projects and expanded capacity. - Xanthine business to expand capacity targeting 9000 metric tonnes by FY26, enhancing volumes and revenues. - Atali project commissioning by Q4 FY25 will add 25-30% capacity, aiding volume growth and improving margin profile. - Gross margins expected to stabilize with improved CDMO contribution but remain subject to competitive pressures, especially in API and Xanthine segments. - Margin impact from trading business shutdown will be minimal due to low margin profile (1-2%). - Continued investment in R&D and capacity expansions to support sustained growth and profitability.

- The company currently has 53 live projects with 18 customers, up from 16 commercial projects six months ago. - There is a strong pipeline of early-phase projects indicating good future growth. - Recent quarters saw an increase in project additions, reflecting higher traction and inquiries. - Commercial projects account for around 27, with over 50-60% in early stages. - CDMO/CMO business had a base revenue of Rs. 170 crore in FY24; guidance for a 25-30% growth over that in FY25. - Project sizes vary, with some inquiries exceeding $1-2 million, but many projects are still ramping up post-validation. - The company anticipates ongoing demand growth supported by capacity expansions such as the Atali facility and flexible plant utilisation.